Phil Nadeau
Stock Analyst at TD Cowen
(4.62)
# 913
Out of 4,698 analysts
786
Total ratings
52.1%
Success rate
10.6%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CABA Cabaletta Bio | Maintained: Buy | n/a | $3.47 | - | 16 | Sep 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Maintained: Buy | $120 | $66.53 | +80.37% | 85 | Aug 20, 2026 | |
| KURA Kura Oncology | Maintained: Buy | n/a | $13.25 | - | 22 | Aug 12, 2026 | |
| ANNX Annexon | Maintained: Buy | n/a | $4.87 | - | 19 | Aug 12, 2026 | |
| IPSC Century Therapeutics | Maintained: Buy | n/a | $2.11 | - | 5 | Aug 12, 2026 | |
| NKTX Nkarta | Maintained: Buy | n/a | $2.92 | - | 2 | Aug 10, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | n/a | $15.01 | - | 20 | Aug 10, 2026 | |
| VYGR Voyager Therapeutics | Maintained: Buy | n/a | $3.51 | - | 43 | Aug 6, 2026 | |
| EDIT Editas Medicine | Maintained: Buy | n/a | $3.23 | - | 28 | Aug 5, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | n/a | $11.39 | - | 21 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $59.32 | - | 18 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $525 → $550 | $546.12 | +0.71% | 87 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $20.56 | - | 22 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $130 | $102.74 | +26.53% | 37 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $200 → $220 | $155.64 | +41.35% | 57 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $215 → $225 | $220.83 | +1.89% | 55 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $7.56 | - | 13 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $22.76 | - | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $20.88 | - | 6 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $9.76 | n/a | 18 | Mar 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0004 | n/a | 27 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $28.49 | n/a | 31 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.96 | n/a | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $12.24 | n/a | 3 | Feb 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $80 → $75 | $151.00 | n/a | 44 | Feb 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $11.99 | n/a | 12 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $1.97 | n/a | 7 | Aug 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $3.86 | n/a | 6 | Feb 26, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $385 | $827.72 | n/a | 40 | Feb 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.83 | n/a | 14 | Jan 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 → $16 | $0.0001 | n/a | 14 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $205 | $437.23 | n/a | 1 | Jul 26, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $2.24 | n/a | 1 | May 3, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $487.61 | n/a | 5 | Apr 28, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $22.50 | n/a | 1 | Aug 7, 2015 |
Cabaletta Bio
Sep 2, 2026
Maintained: Buy
Price Target: n/a
Current: $3.47
Upside: -
BioMarin Pharmaceutical
Aug 20, 2026
Maintained: Buy
Price Target: $120
Current: $66.53
Upside: +80.37%
Kura Oncology
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $13.25
Upside: -
Annexon
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $4.87
Upside: -
Century Therapeutics
Aug 12, 2026
Maintained: Buy
Price Target: n/a
Current: $2.11
Upside: -
Nkarta
Aug 10, 2026
Maintained: Buy
Price Target: n/a
Current: $2.92
Upside: -
MoonLake Immunotherapeutics
Aug 10, 2026
Maintained: Buy
Price Target: n/a
Current: $15.01
Upside: -
Voyager Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: n/a
Current: $3.51
Upside: -
Editas Medicine
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $3.23
Upside: -
Vir Biotechnology
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $11.39
Upside: -
Aug 5, 2026
Maintained: Buy
Price Target: n/a
Current: $59.32
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $525 → $550
Current: $546.12
Upside: +0.71%
Aug 4, 2026
Maintained: Buy
Price Target: n/a
Current: $20.56
Upside: -
Aug 4, 2026
Rated: Buy
Price Target: $130
Current: $102.74
Upside: +26.53%
Jul 31, 2026
Rated: Buy
Price Target: $200 → $220
Current: $155.64
Upside: +41.35%
Jul 30, 2026
Rated: Buy
Price Target: $215 → $225
Current: $220.83
Upside: +1.89%
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $7.56
Upside: -
May 7, 2026
Maintained: Buy
Price Target: n/a
Current: $22.76
Upside: -
Apr 29, 2026
Maintained: Buy
Price Target: n/a
Current: $20.88
Upside: -
Mar 9, 2025
Maintained: Buy
Price Target: n/a
Current: $9.76
Upside: n/a
Nov 13, 2024
Rated: Hold
Price Target: n/a
Current: $0.0004
Upside: n/a
Oct 31, 2024
Maintained: Buy
Price Target: n/a
Current: $28.49
Upside: n/a
Mar 22, 2024
Rated: Hold
Price Target: n/a
Current: $5.96
Upside: n/a
Feb 13, 2023
Downgraded: Hold
Price Target: n/a
Current: $12.24
Upside: n/a
Feb 4, 2021
Maintained: Buy
Price Target: $80 → $75
Current: $151.00
Upside: n/a
Nov 9, 2020
Reiterated: Buy
Price Target: n/a
Current: $11.99
Upside: n/a
Aug 7, 2019
Maintained: Buy
Price Target: n/a
Current: $1.97
Upside: n/a
Feb 26, 2019
Initiated Coverage: Buy
Price Target: n/a
Current: $3.86
Upside: n/a
Feb 6, 2019
Rated: Hold
Price Target: $385
Current: $827.72
Upside: n/a
Jan 17, 2019
Maintained: Hold
Price Target: n/a
Current: $3.83
Upside: n/a
Nov 2, 2018
Maintained: Buy
Price Target: $2 → $16
Current: $0.0001
Upside: n/a
Jul 26, 2018
Rated: Buy
Price Target: $205
Current: $437.23
Upside: n/a
May 3, 2016
Reiterated: Hold
Price Target: n/a
Current: $2.24
Upside: n/a
Apr 28, 2016
Reiterated: Buy
Price Target: $185
Current: $487.61
Upside: n/a
Aug 7, 2015
Reiterated: Hold
Price Target: n/a
Current: $22.50
Upside: n/a